Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue New England Journal of Medicine Année : 2023

Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia

Jean-Pierre Quenot
  • Fonction : Auteur
Renaud Respaud
  • Fonction : Auteur
Denis Garot
  • Fonction : Auteur
Mai-Anh Nay
  • Fonction : Auteur
Ferhat Meziani
  • Fonction : Auteur
Pascal Andreu
  • Fonction : Auteur
Raphaël Clere-Jehl
  • Fonction : Auteur
Noémie Zucman
  • Fonction : Auteur
Marie-Ange Azaïs
  • Fonction : Auteur
Marjorie Saint-Martin
  • Fonction : Auteur
Charlotte Salmon Gandonnière
  • Fonction : Auteur
Dalila Benzekri
  • Fonction : Auteur
Hamid Merdji

Résumé

Background: Whether preventive inhaled antibiotics may reduce the incidence of ventilator-associated pneumonia is unclear. Methods: In this investigator-initiated, multicenter, double-blind, randomized, controlled, superiority trial, we assigned critically ill adults who had been undergoing invasive mechanical ventilation for at least 72 hours to receive inhaled amikacin at a dose of 20 mg per kilogram of ideal body weight once daily or to receive placebo for 3 days. The primary outcome was a first episode of ventilator-associated pneumonia during 28 days of follow-up. Safety was assessed. Results: A total of 850 patients underwent randomization, and 847 were included in the analyses (417 assigned to the amikacin group and 430 to the placebo group). All three daily nebulizations were received by 337 patients (81%) in the amikacin group and 355 patients (83%) in the placebo group. At 28 days, ventilator-associated pneumonia had developed in 62 patients (15%) in the amikacin group and in 95 patients (22%) in the placebo group (difference in restricted mean survival time to ventilator-associated pneumonia, 1.5 days; 95% confidence interval [CI], 0.6 to 2.5; P = 0.004). An infection-related ventilator-associated complication occurred in 74 patients (18%) in the amikacin group and in 111 patients (26%) in the placebo group (hazard ratio, 0.66; 95% CI, 0.50 to 0.89). Trial-related serious adverse effects were seen in 7 patients (1.7%) in the amikacin group and in 4 patients (0.9%) in the placebo group. Conclusions: Among patients who had undergone mechanical ventilation for at least 3 days, a subsequent 3-day course of inhaled amikacin reduced the burden of ventilator-associated pneumonia during 28 days of follow-up. (Funded by the French Ministry of Health; AMIKINHAL ClinicalTrials.gov number, NCT03149640; EUDRA Clinical Trials number, 2016-001054-17.).

Domaines

Pharmacologie
Fichier non déposé

Dates et versions

hal-04475709 , version 1 (23-02-2024)

Identifiants

Citer

Stephan Ehrmann, François Barbier, Julien Demiselle, Jean-Pierre Quenot, Jean-Etienne Herbrecht, et al.. Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. New England Journal of Medicine, 2023, 389 (22), pp.2052-2062. ⟨10.1056/NEJMoa2310307⟩. ⟨hal-04475709⟩
30 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More